Business EconomyPosted at: Apr 24 2024 9:16PM


NSE launches derivatives on Nifty Next 50 Index

Mumbai, Apr 24 (UNI) National Stock Exchange of India Ltd (NSE), the world’s largest derivatives exchange for consecutive fifth year in a row in the year 2023 based on contracts traded as published by FIA, launched futures and options contracts on the Nifty Next 50 Index on Wednesday.

The new derivatives contract has received positive response from market participants. More than 375 trading members from across the country participated in the index derivatives. The trading members involved in execution of the initial trade include East India Securities Limited, and Samco Securities Limited.

The first day witnessed 1,223 number of contracts traded worth Rs. 78.16 crores in Futures and 1,724 number of contracts worth Rs 1.55 crores of premium turnover in Options.

The Nifty Next 50 index provides representation to large capitalisation stocks beyond the Nifty 50 index. The stocks part of the Nifty Next 50 are the potential contenders for being included in the coveted list of 50 stocks forming part of the Nifty 50 index subject to meeting the parameters specified in the index methodology.

The Financial Services Sector has the highest weightage in the index accounting for 23.76% followed by Capital Goods sector with 11.91% and Consumer Services sector with 11.57%.

The Nifty Next 50 index futures and options contracts with its contract symbol “NIFTYNXT50” are available with trading cycle of 3 serial monthly contracts. The derivatives are cash settled with expiry day being the last Friday of the expiry month.

Exchange has provided a transaction fee waiver on the Nifty Next 50 Index derivatives up to October 2024.

On the occasion, Sriram Krishnan, Chief Business Development Officer, NSE, said “We thank all the trading member fraternity and all stakeholders for their tremendous support in successfully launching the derivatives contracts on Nifty Next 50 index. The derivative product is unique considering the underlying index does not have overlapping constituents with the other market capitalisation based broad indices on which derivatives are available on NSE. With increasing interest of participants beyond the top 50 stocks, this index will provide an additional tool for risk management.”
UNI SJC KK
Please log in to get detailed story.
Tags: #NSE launches derivatives on Nifty Next 50 Index
More News

Godrej incorporates subsidiary to enhance financial services presence

14 Jan 2026 | 8:03 PM

Mumbai, Jan 14 (UNI) Godrej Industries Ltd (GIL) has officially announced that it has incorporated a new subsidiary, called Godrej Investment Ltd, as its financial services arm, which will serve as an umbrella holding company for all group financial operations, including its lending businesses.

see more..

Large-Ticket Deals Power Industrial & Warehousing Leasing to 36 9 Mn Sq Ft in 2025: Colliers

14 Jan 2026 | 7:59 PM

Hyderabad, Jan 14( UNI) India’s industrial and warehousing real estate market recorded its strongest performance in recent years, with 36.9 million sq ft of leasing in 2025, registering a 16% year-on-year growth, according to a report released by Colliers India.

see more..

14 Jan 2026 | 7:35 PM

Hyderabad, Jan 14 UNI) : Capital inflows into India’s real estate sector rose sharply in calendar year 2025, reaching an all-time high of USD 14.3 billion, marking a 25 per cent year-on-year growth, according to a latest report ‘ India market Monitor Q4 2025- Investments’ released by CBRE South Asias Pvt Ltd.

see more..

Cyient founder Mohan Reddy receives living leged award by Geospatial World

14 Jan 2026 | 7:18 PM

Hyderabad, Jan 14 (UNI) Cyient, a global Intelligent Engineering solutions company, on Wednesday announced that its Founder Chairman, Dr. B.V.R. Mohan Reddy, has been conferred the ‘Living Legend Award’ by Geospatial World, one of the world’s leading geospatial knowledge organisations.

see more..

Dr Reddy’s launches first to market OTC antihistamine eye drop in US

14 Jan 2026 | 6:54 PM

Hyderabad, Jan 14 (UNI) : Dr. Reddy’s Laboratories on Wednesday announced the first-to-market U.S. launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once-Daily Relief, following approval by the U.S. Food and Drug Administration.

see more..